When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
One stock that fits that bill is CRISPR Therapeutics, which saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 86 to 91.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength. This exclusive rating from Investor's Business Daily measures price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an 80 or better RS Rating in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
CRISPR Therapeutics is not currently near a potential buying area. See if the stock goes on to form a base that could kick off a new price move.
CRSP Earnings
CRISPR Therapeutics reported 0% earnings growth in the latest quarterly report, while sales growth came in at 10,538%.
The company earns the No. 30 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm, Arcturus Therapeutics and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
